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Abstract
Surrogate endpoints are very important in regulatory decision-making in healthcare, in particu-
lar if they can be measured early compared to the long-term final clinical outcome and act as good
predictors of clinical benefit. Bivariate meta-analysis methods can be used to evaluate surrogate
endpoints and to predict the treatment effect on the final outcome from the treatment effect mea-
sured on a surrogate endpoint. However, candidate surrogate endpoints are often imperfect, and
the level of association between the treatment effects on the surrogate and final outcomes may vary
between treatments. This imposes a limitation on the pairwise methods which do not differentiate
between the treatments. We develop bivariate network meta-analysis (bvNMA) methods which
combine data on treatment effects on the surrogate and final outcomes, from trials investigating
heterogeneous treatment contrasts. The bvNMA methods estimate the effects on both outcomes for
all treatment contrasts individually in a single analysis. At the same time, they allow us to model
the surrogacy patterns across multiple trials (different populations) within a treatment contrast and
across treatment contrasts, thus enabling predictions of the treatment effect on the final outcome
for a new study in a new population or investigating a new treatment. Modelling assumptions about
the between-studies heterogeneity and the network consistency, and their impact on predictions,
are investigated using simulated data and an illustrative example in advanced colorectal cancer.
When the strength of the surrogate relationships varies across treatment contrasts, bvNMA has the
advantage of identifying treatments for which surrogacy holds, thus leading to better predictions.
1 Introduction
Surrogate endpoints are very important in the drug development process, at both the trial design
and the evaluation stage. They are particularly useful when they can provide early measurement
of the treatment effect, in settings where a long follow up time is required before measurement of
the final clinical outcome [6]. This is often the case in cancer where overall survival (OS) is of
primary interest whilst other outcomes such as progression-free survival (PFS) potentially can be
used to measure the effect of a treatment earlier. Alternatively, PFS may be of primary interest
and tumour response (TR) is then investigated as a short term surrogate endpoint to PFS. Before
they can be used in evaluation of new health technologies, candidate surrogate endpoints have to
be assessed for their predictive value of the treatment effect on the final clinical outcome. Surrogate
outcomes are validated by estimating the pattern of association between the treatment effects on
surrogate and final endpoints across trials using meta-analytic techniques [10, 8, 7, 18, 3, 2].
Multivariate meta-analysis methods are used to obtain average treatment effects on multiple
endpoints while taking account of the correlations between them [20, 19, 22, 4] and, as such, are
suitable tools for modelling surrogate endpoints [3, 2]. Bivariate meta-analysis (bvMA) of treatment
effects on a surrogate and a final outcome allows for both the validation of a surrogate endpoint
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and for making predictions of an unobserved treatment effect on the final clinical outcome from
observed treatment effects on a surrogate endpoint.
Candidate surrogate endpoints often are not perfect, and the association patterns between the
treatment effects on the surrogate and final outcomes may vary between treatments. Whilst bvMA,
described in detail in Section 3, can be used to model surrogate endpoints, it does not differentiate
between the treatment options. This is an important issue when the evidence base consists of mul-
tiple trials of different treatments in different populations. Network meta-analysis (NMA) combines
data from trials investigating heterogeneous treatment contrasts and has the advantage of estimat-
ing effects for all treatment contrasts individually. At the same time, the consistency assumption
allows for combining evidence (and borrowing strength) across the treatment contrasts. In this
paper, we will exploit this framework to model surrogacy relationships by extending previously
reported methods of multivariate NMA [1, 11, 12, 13].
In the multivariate NMA (mvNMA), true treatment effects on multiple correlated outcomes are
assumed to follow separate multivariate distributions for each treatment contrast. The previously
reported mvNMA methods typically simplified the between-studies variance-covariance structures
by assuming homogeneity of the correlations and the heterogeneity parameters across the treatment
contrasts. We relax this assumption of homogeneity to model in detail different association patterns
between the effects on surrogate and final endpoints separately for different treatments or treatment
classes. By allowing such patterns to differ across treatments, the methodology can help to identify
treatments for which the surrogacy holds and to improve predictions. The network consistency
assumption provides a framework for combining evidence across treatment contrasts and hence
modelling and distinguishing surrogacy patterns within and across treatment contrasts. These two
levels of surrogacy enable predictions of the treatment effect on the final outcome in a new study
investigating either an existing treatment in a new population (within treatment contrast surrogacy)
or a new treatment (across treatment surrogacy). We extend the second order consistency condition,
described by Lu and Ades [16] in a univariate NMA, to the bivariate case, in order to gain additional
precision in modelling surrogate relationships.
We illustrate the use of the methods, described in Sections 3 and 4, by fitting them to data
from an example in advanced colorectal cancer introduced in Section 2 (results presented in Section
5). To illustrate the motivation and the application of the methodology in a more detailed and
controlled manner, we apply the methods to simulated data scenarios (Section 6). We fit all models
in a Bayesian framework using the OpenBUGS software.
2 Illustrative example
We use data from randomised controlled trials (RCTs) in advanced colorectal cancer (aCRC),
investigating a range of different treatment options, to illustrate how the hierarchical bvNMA
models, proposed in this paper, can differentiate the association patterns between the treatment
contrasts or classes whilst borrowing strength across treatment contrasts. Data were obtained from
four published systematic reviews of RCTs investigating pharmacological treatments in aCRC,
categorised into classes with respect to their mechanism of action. These were targeted therapies
including antiangiogenic treatments targeting vascular endothelial growth factor (anti-VEGF) [21],
anti epidermal growth factor receptor inhibitors (EGFRi) [9], humanised monoclonal antibody
targeting integrin receptors (anti-IgG2) and monoclonal antibody targeting the type 1 insulin-like
growth factor receptor (anti-IGF1R) [17] or chemotherapies compared to the targeted therapies [17,
14] and combinations of these therapies. 15 RCTs investigated use of anti-VEGF with chemotherapy
vs. chemotherapy alone, 24 RCTs of EGFRi with chemotherapy vs. chemotherapy alone, 4 RCTs
of EGFRi with chemotherapy vs. anti-VEGF with chemotherapy, 4 RCTs of EGFRi with anti-
VEGF and chemotherapy vs. anti-VEGF with chemotherapy, one study (in two subgroups of
population) of anti-IgG2 with EGFRi and chemotherapy vs. EGFRi with chemotherapy, one study
of anti-IGF1R with chemotherapy vs. chemotherapy alone and one of EGFRi with anti-VEGF and
chemotherapy vs. chemotherapy alone. The treatments are summarised in the network diagram
of Figure 1. Tumour response (TR) is used as an example of a potential surrogate endpoint to
progression free survival (PFS). The models are applied to data representing treatment effect on
the two outcomes on log odds ratio (OR) scale for TR and log hazard ratio (HR) scale for PFS.
The scatter plot in Figure 1 illustrates the association patterns between the treatment effects on
the two outcomes for each treatment contrast.
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Figure 1: Scatter plot and network diagram for the advanced colorectal cancer example, A – chemother-
apy alone, B – anti-VEGF therapies + chemotherapy, C – EGFRi + chemotherapy, D – EGFRi +
anti-VEGF therapies + chemotherapy, E – anti-IGF1R , F – anti-IgG2 + chemotherapy
3 Bivariate random effects meta-analysis (BRMA)
The bivariate random effects meta-analysis (BRMA) model for correlated and normally distributed
treatment effects on two outcomes Y1i and Y2i is usually presented in the form described by van
Houwelingen et al. [20] and Riley et al. [19]:(
Y1i
Y2i
)
∼ N
{(
µ1i
µ2i
)
,Σi
}
, Σi =
(
σ21i σ1iσ2iρwi
σ1iσ2iρwi σ
2
2i
)
(1)(
µ1i
µ2i
)
∼ N
{(
β1
β2
)
,T
}
, T =
(
τ21 τ1τ2ρ
τ1τ2ρ τ
2
2
)
. (2)
In this model, the treatment effects on the surrogate endpoint Y1i and on the final outcome Y2i
are assumed to estimate the correlated true effects µ1i and µ2i with corresponding within-study
variances σ21i and σ
2
2i of the estimates and the within-study correlation ρwi between them. In
this hierarchical framework, these true study-level effects follow a bivariate normal distribution
with means (β1, β2) corresponding to the two outcomes, between-studies variances τ
2
1 and τ
2
2 and
a between-studies correlation ρ. Equation (1) represents the within-study model and (2) is the
between-studies model. To implement the model in the Bayesian framework, prior distributions
are placed on the mean effects, for example vague prior distributions β1 ∼ N(0, 104), β2 ∼ N(0, 104)
and on the between-studies variances and correlation.
In the general case, for any number of outcomes, a prior distribution has to be placed on the
whole variance-covariance matrix or the correlation matrix in such a way to ensure that the variance-
covariance matrix is positive semi-definite. This can be achieved by placing an inverse Wishart prior
distribution on the variance-covariance matrix [22] or by using a separation strategy, with spherical
[16, 22] or Cholesky decomposition [22] of the correlation matrix. Alternatively, a product normal
formulation of the between-studies model can be used where the model is parameterised in the
form of a series of univariate conditional distributions, ensuring that the relationships between the
parameters of the model (regression coefficients and conditional variances) and the elements of
the between-studies variance-covariance matrix result in the positive semi-definite between-studies
variance-covariance matrix [4, 3, 2].
In the bivariate case, such as considered here, positive semi-definiteness can be achieved by
placing prior distributions on the variances, which are restricted to plausible positive values, for
example by placing uniform prior distributions on the corresponding standard deviations τj ∼
U(0, 2), and by choosing a prior distribution for the correlation which restricts it to values between
−1 and +1. Here we use a beta distribution to construct such a prior: ρ+12 ∼ Beta(1.5, 1.5), as in
Burke et al. [5], with details also in the Appendix A.
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4 Bivariate network meta-analysis (bvNMA)
The BRMA model is typically used to obtain average effects on two correlated outcomes, for studies
of the same treatment or treatment class. In the context of surrogate endpoints, data on a range
of treatments are typically used. BRMA assumes exchangeability of the treatment effects from all
studies regardless of the treatment contrast, by assuming that the true effects follow a common
(here bivariate normal) distribution (as in Eq. (2)). This model works well for strong surrogate
relationships across all treatments. However, the association pattern between treatment effects
measured on the surrogate and final outcomes may depend on the treatment contrast. Network
meta-analysis can differentiate between treatment contrasts and in bivariate form can be applied
to modelling such surrogate relationships within and across treatment contrasts. We first discuss
general bvNMA models in Section 4.1 which describe the within-treatment surrogate relationships
in the network. In Section 4.2 we extend these models to allow for an additional level of surrogacy
across treatment contrasts.
4.1 General bvNMA models
4.1.1 Model 1a: bvNMA
To model correlated treatment effects on a surrogate endpoint and a final outcome for which the
correlation varies according to the treatment contrasts, the assumption made by BRMA, that the
true effects follow a common distribution, can be replaced by an assumption that the true effects
corresponding to different treatment contrasts follow separate distributions. This naturally leads
to relaxing the assumption of homogeneity of the between-studies covariance matrix, allowing its
elements (the between-studies correlations ρ1kl,2kl between the treatment effects l vs. k on the
surrogate (1) and final (2) outcomes and the heterogeneity parameters for the treatment effects on
the two outcomes τ21kl and τ
2
2kl) to vary across the treatment contrasts kl.
To take into account the network structure of the data, we model the treatment effect differences
Yjkli between treatments k and l in study i for outcome j = 1, 2, as follows:(
Y1kli
Y2kli
)
∼ N
{(
µ1kli
µ2kli
)
,Σi
}
, Σi =
(
σ21kli σ1kliσ2kliρwkli
σ1kliσ2kliρwkli σ
2
2kli
)
(3)(
µ1kli
µ2kli
)
∼ N
{(
d1kl
d2kl
)
,
(
τ21kl τ1klτ2klρ1kl,2kl
τ1klτ2klρ1kl,2kl τ
2
2kl
)}
(4)
where k and l denote baseline (control) and experimental treatments respectively in a study i, µjkli
denote the random true treatment effects (differences between the effects of treatments k and l) on
outcome j in study i and, and the djkl are mean treatment effect differences between treatments k
and l for each outcome j. We use the first-order consistency assumption, as described by Lu and
Ades [16], extended here to the bivariate case. For any three treatments (b, k, l), the treatment
differences (µjkli) satisfy the following transitivity relations(
µ1kli
µ2kli
)
=
(
µ1bli − µ1bki
µ2bli − µ2bki
)
. (5)
Taking the expectation on both sides gives the consistency equations for the first-order moments(
d1kl
d2kl
)
=
(
d1bl − d1bk
d2bl − d2bk
)
(6)
which represent the relationships between the treatment contrasts in the population. When b = 1
is a common reference treatment in the network, the treatment effects of each treatment k in the
network relative to this common reference treatment 1; the dj,1k are referred to as basic parameters
for each outcome j, with dj,11 = 0 and the others are given prior distributions:
dj,1k ∼ N(0, 103). (7)
Prior distributions are also placed on the elements of the between-studies variance-covariance ma-
trix. Similarly as in BRMA, prior distributions for the heterogeneity parameters are selected in a
way to ensure that they are restricted to plausible positive values, such as τjkl ∼ unif(0, 2) and for
the correlations to ensure restriction to the values between −1 and 1, e.g. ρkl+12 ∼ Beta(1.5, 1.5),
thus guaranteeing that the variance-covariance matrix is positive semi-definite.
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4.1.2 Model 1b: bvNMA with second order consistency
The above meta-analytic model 1a assumes consistency of treatment effects on both outcomes.
This implies some constraints on the between-studies variance-covariance matrices which can be
explicitly introduced to the bvNMA model (3)–(4) by assuming the consistency of the second-order
moments. To do so, we extend the approach proposed by Lu and Ades [16] to the bivariate case
by taking variances on both sides of the transitivity equation (5), which gives(
τ21kl τ1klτ2klρ1kl,2kl
τ1klτ2klρ1kl,2kl τ
2
2kl
)
=
(
var(µ1bli − µ1bki) cov(µ1bli − µ1bki, µ2bli − µ2bki)
cov(µ1bli − µ1bki, µ2bli − µ2bki) var(µ2bli − µ2bki)
) (8)
leading to the following relationship between the variances for any three treatments (b, k, l) and for
both outcomes j = 1, 2:
τ2jkl = τ
2
jbk + τ
2
jbl − 2ρjbk,jblτjbkτjbl ≤ (τjbk + τjbl)2, (9)
which gives the second-order consistency conditions (triangle inequalities):
|τjbl − τjbk| ≤ τjkl ≤ τjbl + τjbk. (10)
In addition, the following condition applies to the covariances:
τ1klτ2klρ1kl,2kl = τ1blτ2blρ1bl,2bl + τ1bkτ2bkρ1bk,2bk − τ1blτ2bkρ1bl,2bk − τ1bkτ2blρ1bk,2bl, (11)
which implies further constraints that are more complex than those in Eq. (10).
To ensure that prior distributions for heterogeneous variance-covariance matrices are appropri-
ate, i.e. to maintain the second-order consistency condition for any three treatments in the network,
bivariate ancillary parameters are used, extending the univariate model by
To ensure that prior distributions for heterogeneous variance-covariance matrices are appro-
priate, i.e. to maintain the second-order consistency condition for any three treatments in the
network, bivariate ancillary parameters are used, similarly as by Lu and Ades [16], allowing the
between-studies variance-covariance matrices to be represented as(
τ21kl τ1klτ2klρ1kl,2kl
τ1klτ2klρ1kl,2kl τ
2
2kl
)
=

γ21k + γ
2
1l − 2ξ1k,1lγ1kγ1l
γ1kγ2kξ1k,2k − γ1kγ2lξ1k,2l
−γ1lγ2kξ1l,2k + γ1lγ2lξ1l,2l
γ1kγ2kξ1k,2k − γ1kγ2lξ1k,2l
−γ1lγ2kξ1l,2k + γ1lγ2lξ1l,2l γ
2
2k + γ
2
2l − 2ξ2k,2lγ2kγ2l
 (12)
where γ2jk and γ
2
jl are the ancillary parameters: the variances of two correlated random effects ζjki
and ζjli corresponding to treatment arms k and l (for each outcome j = 1, 2). Prior distributions for
the set of between-studies standard deviations τjkl for each outcome j and each pair of treatments
k and l can be given by constructing a prior distribution for a covariance matrix Γ composed of the
standard deviations γjk and the correlations ξjk,j′l between the effects ζjki and ζj′li, for j, j
′ = 1, 2
and k, l = 1, . . . , nt, where nt is the number of treatments in the network. For the set of values
of the elements of matrix Γ to give a resulting set of standard deviations τjkl that satisfy the
second-order consistency rules (10) and (11), the matrix Γ has to be positive semi-definite. This
is achieved using a separation strategy with a Cholesky decomposition: Γ = V 1/2RV 1/2, where
V 1/2 is a 2nt × 2nt diagonal matrix of the standard deviations γ11, γ21, . . . , γ1nt , γ2nt and R is a
positive semi-definite 2nt × 2nt matrix of correlations ξjk,jˆl (block matrix consisting of nt × nt
blocks that are of 2× 2 dimension). Matrix R is represented as R = LTL with L being a 2nt× 2nt
upper triangular matrix. To obtain the elements of the matrix L, we extended the method by
Wei and Higgins (2013) who describe it for a four dimensional matrix case. Prior distributions
are placed on the standard deviations, which need to be restricted to positive values, for example
γj,k ∼ unif(0, 2). The prior distributions placed on the ancillary variances and correlations give
implied prior distributions on the between-studies correlations and standard deviations through the
formulae (12).
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4.1.3 Model 1c: bvNMA with second order consistency and similarity of the
ancillary parameters
To ensure second order consistency of the treatment effects in the network, model 1b requires
estimation of relatively many parameters. Where data for each treatment k is only available from a
limited number of studies, it may be difficult to estimate the individual variances γ21k. To overcome
this issue, exchangeability of the ancillary variances may be assumed by replacing individual prior
distributions for these parameters with a common distribution;
γ2jk ∼ N(0, vj)I(0, ) and vj ∼ Γ(1.0, 0.01). (13)
4.1.4 Model 1d: bvNMA assuming homogeneity of the between-studies variance-
covariance matrix
When networks are sparse, instead of assuming similarity between the heterogeneity parameters,
as in Eq. (13), homogeneity of the between-studies variance-covariance matrix can be assumed,
which is a common assumption in the multivariate network meta-analysis or the univariate network
meta-analysis of multi-arm trials [15]. The between-studies equation (4) then becomes(
µ1kli
µ2kli
)
∼ N
{(
d1,1l − d1,1k
d2,1l − d2,1k
)
, T =
(
τ21 τ1τ2ρ
τ1τ2ρ τ
2
2
)}
(14)
where µjkli is the random treatment effect difference between treatments k and l on outcome j in
study i and dj,1k is the mean treatment effect difference between treatment k and the reference
treatment 1 for outcome j, with dj,11 = 0. A prior distribution is placed on each basic parameter,
dj,1k ∼ N(0, 103). A prior distribution is also placed on the elements of the common between-
studies variance-covariance matrix: the between-studies standard deviations, τj ∼ Unif(0, 2) and
the correlation, ρ+12 ∼ Beta(1.5, 1.5).
4.1.5 Surrogacy criteria:
When using the bivariate NMA models 1a-c to evaluate surrogate endpoints within treatment
contrast kl, perfect surrogacy means that
ρ1kl,2kl = ±1 and µ1kli = 0 ⇔ µ2kli = 0. (15)
This condition is equivalent to assuming that in the linear relationship between true treatment
effects on the final and surrogate endpoints, the intercept is zero, µ2kli = const × µ1kli and the
conditional variance (of the treatment effect on the final outcome conditional on the effect on the
surrogate endpoint) is also zero, as in the standard surrogacy models [10, 3] (for more details see
Appendix B).
This criterion describes the between-studies (and populations) surrogacy relationships within
the treatment contrasts. The network structure, with the unique surrogate relationship for each
treatment contrast, can help us to disentangle information about a surrogate relationship for a par-
ticular treatment and to make better predictions, in particular when these relationships are clearly
distinct, as illustrated in Section 6. These individual surrogacy relationships enable predicting the
treatment effect on the final outcome from the treatment effect measured on a surrogate endpoint
in a new study investigating an existing treatment either in a new population or with a different
(but already present in the network) control treatment.
When evaluating surrogate endpoints with model 1d, similarly as for models 1a-c the random
effects are assumed to follow separate distributions for studies evaluating different treatment con-
trasts kl but the between-studies correlations and heterogeneity parameters are assumed to be the
same across the treatment contrasts. In this case, the perfect surrogacy means that
ρ = ±1 and µ1kli = 0 ⇔ µ2kli = 0 (16)
which differs from the criteria for the models 1a-c with respect to the common correlation across
the treatment contrasts. The strength of the association between the treatment effects on the
surrogate endpoint and the final clinical outcome will be the same across the treatment contrasts
when using model 1d, similarly as when using a pairwise meta-analysis such as BRMA. However,
assuming that the random effects for different treatment contrasts follow separate distributions in
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the bvNMA, we model these association patterns in more detail compared to when using BRMA.
In addition, taking into account the network structure of the data results in borrowing of strength
across the treatment contrasts when evaluating surrogate relationships.
4.2 bvNMA models with borrowing of strength across treatment con-
trasts
Models 1a–d describe the relationships between the treatment effects on correlated outcomes when
for each treatment contrast in the network there is at least one study reporting the treatment
effects on both outcomes. In the situation where we want to predict the treatment effect on the
final outcome from the effect on the surrogate endpoint in a new study evaluating a new treatment,
there will be only this one study reporting the effect for that treatment and only on the surrogate
endpoint. In this case the above models 1a–d will result in an estimate of the average effect on
the final outcome for the new treatment based solely on the prior distribution, because no data
are available for the effect of this treatment on the final outcome. For example, as in the network
depicted in Figure 2, if we select treatment A as the reference treatment 1, then the average
treatment effect for the new treatment D on the final outcome equals d2,CD = d2,AD − d2,AC and
the estimate of the basic parameter d2,AD would be based on the prior distribution only. As a
result, the estimate of the between-studies correlation ρ1CD,2CD will be based solely on the prior
distribution. Therefore the predicted treatment effect on the final outcome from the treatment
effect on the surrogate endpoint for the new treatment will not be meaningful. The models 1a–d
are designed to evaluate surrogacy patterns across different populations within a treatment contrast
and make predictions of a treatment effect on the final outcome in a new study investigating an
existing treatment only, but perhaps in a new population.
A
B C
D
1
A
B C
Figure 2: Example network diagram: data on effect of new treatment D only available in one new
study and only measured on surrogate endpoint (left) but not on the final outcome (right).
4.2.1 Model 2a: assuming exchangeability of treatments
To overcome the above issue, an exchangeability assumption can be made to allow for the rela-
tionships between the average effects on the two outcomes to be similar across treatment options.
To achieve this for model 1a (Eqs (3), (4) and (6)), instead of placing a prior distribution on each
basic parameter (Eq. (7)), it is assumed that the pooled effects for each treatment arm k, θjk on
the two outcomes j = 1, 2, are exchangeable and correlated:
dj1k = θjk − θj1, (17)(
θ1k
θ2k
)
∼ N
((
η1
η2
)
,
1
2
(
ω21 ω1ω2ρt
ω1ω2ρt ω
2
2
))
(18)
for k = 1, . . . , nt. Assuming exchangeability of the effects in each treatment arm θjk, rather than of
the basic parameters dj1k which are the effects relative to a common reference treatment, ensures
that the prior distributions for each pair (θ1k, θ2k) are independent.
The modelled data Yjkli are the treatment effect differences, thus the ancillary parameters
θjk are not identifiable. However, we are not interested in estimating these parameters, but in
estimation of the association between the average treatment effect differences on the two outcomes:
djkl, j = 1, 2. The above formulae imply the association between the average effects:(
d1kl
d2kl
)
∼ N
{(
0
0
)
,
(
ω21 ω1ω2ρt
ω1ω2ρt ω
2
2
)}
, (19)
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k = 2, . . . , nt, cancelling out the mean values ηj . Therefore the mean values can be set arbitrarily
to a constant, for example ηj = 0. Prior distributions are placed on the elements of the covariance
matrix: ωj ∼ Unif(0, 2) and ρt+12 ∼ Beta(1.5, 1.5). Borrowing of strength across treatments by
relating these parameters enables the model to predict the effect of a new treatment on the final
outcome, as in the network scenario in Figure 2.
4.2.2 Model 2b: assuming exchangeability of treatments, with second order
consistency constraints
We extend model 1b, described by the general mvNMA (3)–(4) along with the first (6) and second
order (10–11) consistency assumptions, to allow for the exchangeability of basic parameters. Sim-
ilarly as in model 2a, this replaces the individual prior distributions on the basic parameters (7)
with the formulae (17)–(18), with prior distributions as in Section 4.2.1.
4.2.3 Model 2c: assuming exchangeability of treatments, with second order
consistency constraints and exchangeable variances in treatment arms
This model is an extension of model 1c, assuming similarity across the ancillary parameters de-
scribed by (13), to allow for the exchangeability of the basic parameters using the formulae (17)–
(18), as in models 2a and 2b.
4.2.4 Model 2d: assuming exchangeability of treatments and homogeneity of
the between-studies variance-covariance matrix
To extend model 1d to allow for the exchangeability of the correlated basic parameters, we used
equations (3) and (14) together with the exchangeability model (17)–(18) on the basic parameters.
As in model 1d, prior distributions are placed on the elements of the common between-studies
variance-covariance matrix, the between-studies standard deviations, τj ∼ Unif(0, 2) and the cor-
relation, ρ+12 ∼ Beta(1.5, 1.5).
4.2.5 Surrogacy criteria
Similarly as for models 1a-d, the surrogate relationship between the treatment effects on the sur-
rogate endpoint and the final clinical outcome is perfect when the correlation ρkl = ±1 (ρ ± 1 for
model 2d) and no treatment effect on the surrogate endpoint (µ1kli = 0) will imply no effect on
the final outcome (µ2kli = 0) in the same study i, as described by the formulae (15) and (16).
This is the surrogacy relationship between studies (or populations) described within each treat-
ment contrast kl and it is assumed to differ across treatment contrasts. In addition to this, another
level of surrogate relationship is described by models 2a-d, the across-treatments surrogacy. Such
a surrogate relationship would be perfect if
ρt = ±1, and d1,kl = 0 ⇔ d2,kl = 0, (20)
a zero average treatment effect difference between treatments k and l on the surrogate endpoint
will imply zero average treatment effect also on the final clinical endpoint for the same treatment
contrast. This surrogacy relationship allows prediction of the treatment effect on the final outcome
from the treatment effect measured on a surrogate endpoint in a new study investigating a new
treatment.
4.3 Summary and discussion of models
Bivariate models for network meta-analysis described in this Section differ in their specific assump-
tions about the heterogeneity between studies and treatments. All components of the between-study
models for all models, 1a–d and 2a–d, are summarised in Table 1. The models allow the correlations
between the treatment effects on the surrogate and final endpoints to vary to a different degree, and
which model is applied in practice can be determined based on the available evidence. The models
reduce to the standard meta-analysis model for surrogate endpoints, such as the BRMA model
(1)–(2), in a special case of data structure when there are only two treatments in the network, as
detailed in Appendix C.
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Assumptions for the between-studies variance-covariance matrix
varying second homogeneity prior
variance- order exchangeable of variance- distributions exchangeable
-covariance consistency ancillary -covariance on basic treatments
model matrix Eqs parameters matrix parameters Eqs
Eq. (4) (10)–(11) Eq. (13) Eq. (14) Eq. (7) (17)–(18)
1a X X
1b X X X
1c X X X X
1d NA X X
2a X X
2b X X X
2c X X X X
2d NA X X
Table 1: Components of each model in terms of the assumptions made about the between-studies
variance-covariance (v-c) matrix.
4.3.1 Strategies for model comparison
To make comparisons between the models, in the first instance the between-studies correlations
(as well as the mean effects and the heterogeneity parameters) are obtained and compared across
the models. Following this, predicted values (and corresponding credible intervals (CrIs)) of the
treatment effects on the final outcome are compared to the observed estimates (and corresponding
confidence intervals (CIs)) in take-one-out cross-validation procedure. In one study at a time, the
estimate of the treatment effect on the final outcome Y2i is removed (and treated as missing at ran-
dom) and then this treatment effect is predicted from the treatment effect on the surrogate endpoint,
conditional of the data on both outcomes from all the remaining studies in the meta-analysis. The
standard deviation of the predicted effect Yˆ2i is equal to
√
σ22i + var(µˆ2(kl)i|Y1i, σ1i, Y1(−i), Y2(−i)),
where Y1(−i) and Y2(−i) denote the data from the remaining studies without the validation study i
(the treatment contrast subscripts, present only in the network meta-analysis, have been dropped
here).
The models were compared with respect to the predicted effects by investigating a number
of statistics obtained from each model: a) proportion of the CI of the observed estimate of the
effect on the final outcome overlapping with the CrI of the predicted effect, poverlap, b) mean
absolute difference between observed estimate of mean effect and predicted mean effect on the
final outcome across studies, |mobs − mpred|, c) ratio of the width of intervals; the width of CrI
of the predicted effect to the width of the CI of the observed effect (the estimate), wpred/wobs, d)
percentage reduction in uncertainty measured by the width of the CrI of the predicted effect when
using a mvNMA model, wNMA, compared to the width of the CrI obtained from BRMA wBRMA;
%red = 100wBRMA−wNMAwBRMA , and e) a new statistic measuring overall performance of a model giving a
higher score for models resulting in large poverlap with penalty for overly inflated predicted interval:
pi =
poverlap
wpred/wobs
, which is always positive and less than one.
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5 Results for aCRC data
In this section we present results of applying all models (BRMA, 1a-d and 2a-d) to the illustra-
tive example in aCRC, introduced in Section 2. Table 2 shows the between-studies correlations
obtained from all the models applied to the aCRC data. The correlations are the parameters of
the primary interest as they tell us about the strength of the surrogate relationships (see Sections
4.1.5 and 4.2.5). Additional results, the average effects and heterogeneity parameters, are included
in Appendix D. When applying BRMA to data from all studies (regardless of the treatment con-
trast), the between-studies correlation is negative, -0.73 (95% CrI: -0.89, -0.49), indicating that
treatment increasing the odds of tumour response leads to reduced progression rate. As shown in
the scatter plot in Figure 1, the distributions of the treatment effects on the two outcomes: log
OR of TR (surrogate endpoint) and log HR of PFS (final outcome), representing their association
patterns, vary across the treatment contrasts. When applying NMA models 1a-c and 2a-c to the
data, the between-studies correlations differ across treatment contrasts, with the highest correlation
obtained for treatment contrast AC (the results are presented only for those contrasts for which
at least four studies were available, the remaining results are included in Appendix D). When ap-
plying model 1b, assuming second order consistency and hence imposing additional constraints on
the between-studies variance-covariance matrices, the correlations were estimated with higher pre-
cision compared to those obtained from model 1a. Applying model 1c slightly inflated the credible
intervals of the correlations for some of the treatment contrasts (AC and BC) and reduced them
for others (AB and BD) (compared to model 1b), which is likely due to the assumption of similar
variances for the effects in each treatment arm not being reasonable for these data. The DIC value,
shown in the right-hand-side column of the table, is also relatively high for model 1c and indicates
poor model fit. A similar pattern is observed across models 2a-c. When assuming homogeneous
variance-covariance matrices in models 1d and 2d, the between-studies correlations are high and
obtained with higher precision compared to the correlation obtained from BRMA. This is likely
due to the borrowing of strength across treatment contrasts, by adding information from the in-
direct comparisons. Based on the DIC criteria, models 1d, 2a, 2b and 2d appear to fit the data
best, although models 1a and 1b appear to have a comparable fit. Prediction of the treatment
effect on PFS (the final outcome) from the treatment effect on TR (the surrogate endpoint) for the
treatment contrast AE, for which only one study was available (new treatment scenario), was not
possible for models 1a–d, due to lack of data to estimate the surrogate relationship. Models 2a–d,
assuming exchangeability of the average effects in each treatment arm across treatment contrasts,
allowed us to make such a prediction. A forest plot of the observed and predicted (from BRMA
and model 2d) effects on PFS is included in Figure 3. The advantage of using bvNMA methods
varied across the treatment contrasts, depending on the surrogacy relationships for each contrast.
Table 2 also shows the across-treatment correlation ρt indicating, consistently across models 2a–d,
a weak surrogate relationship across the treatment contrasts.
Table 3 shows statistics for model comparison, introduced in Section 4.3.1, for each treatment
contrast where at least four studies were available and across all the studies. For example, for the
treatment contrast AB, the use of bvNMA improved the precision of the predictions in terms of the
point estimate, reducing the bias from 0.23 (obtained from BRMA) to between 0.16 and 0.18. All
bvNMA methods gave reduced predicted intervals for the treatment effect on PFS (from the effect
on TR) compared to those obtained from BRMA, by between 11.2% and 16.5%. For contrasts
AC and BC, model 1a did not contribute to reduced uncertainty of predictions, but additional
assumptions of second order consistency (models 1b and 2b) and additional borrowing of strength
(models 1c and 2c) or assumption of homogeneity of the correlations and heterogeneity parameters
(models 1d and 2d) led to improved precision. Results from a sensitivity analysis of the data with
outlying observations removed are presented in Appendix E. For the treatment contrast BD, both
sets of models 1a–b and 2a–b resulted in inflated predicted intervals. The final part of Table 3 lists
the average statistics across all treatments.
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Figure 3: Predicted effects obtained from BRMA and model 2d along with the observed estimates of
the effects on PFS for aCRC data
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poverlap |mobs −mpred| wpred/wobs pi %red.
AB
BRMA 0.89 0.23 2.2 0.45
model 1a 0.91 0.18 1.88 0.54 14.64
model 1b 0.91 0.17 1.95 0.52 11.22
model 1c 0.89 0.17 1.82 0.54 16.54
model 1d 0.89 0.16 1.85 0.53 14.18
model 2a 0.91 0.18 1.91 0.53 13.55
model 2b 0.9 0.17 1.95 0.52 11.25
model 2c 0.89 0.17 1.83 0.54 16.33
model 2d 0.89 0.16 1.84 0.53 14.76
AC
BRMA 0.92 0.24 1.91 0.5
model 1a 0.95 0.23 1.93 0.51 -1.27
model 1b 0.92 0.24 1.8 0.52 5.42
model 1c 0.88 0.24 1.7 0.53 10.41
model 1d 0.86 0.24 1.64 0.54 13.28
model 2a 0.94 0.23 1.93 0.51 -1.02
model 2b 0.91 0.24 1.79 0.52 6.05
model 2c 0.87 0.24 1.69 0.53 10.88
model 2d 0.86 0.24 1.63 0.54 14.06
BC
BRMA 0.97 0.17 2.24 0.47
model 1a 1.00 0.08 3.05 0.4 -30.83
model 1b 0.97 0.09 2.12 0.5 6.22
model 1c 0.95 0.09 1.83 0.56 17.91
model 1d 0.95 0.1 1.9 0.53 14.4
model 2a 1.00 0.08 2.93 0.41 -26.52
model 2b 0.97 0.08 2.09 0.51 7.49
model 2c 0.95 0.07 1.79 0.57 19.81
model 2d 0.95 0.09 1.89 0.54 14.87
BD
BRMA 0.83 0.29 1.86 0.46
model 1a 1.00 0.23 4.58 0.24 -144.64
model 1b 1.00 0.23 3.92 0.27 -109.09
model 1c 0.84 0.25 1.8 0.49 2.7
model 1d 1.00 0.14 1.79 0.58 3.52
model 2a 1.00 0.21 3.67 0.29 -97.09
model 2b 1.00 0.21 3.11 0.34 -65.92
model 2c 0.84 0.24 1.67 0.52 9.54
model 2d 1.00 0.13 1.73 0.59 6.57
All
BRMA 0.91 0.23 1.99 0.49 0
model 1a 0.91 0.2 2.38 NA -22.58
model 1b 0.89 0.2 2.21 NA -14.84
model 1c 0.86 0.2 1.7 NA 13.97
model 1d 0.86 0.19 1.68 NA 14.86
model 2a 0.95 0.2 2.36 0.46 -22.76
model 2b 0.93 0.2 2.14 0.49 -11.77
model 2c 0.89 0.2 1.73 0.54 11.52
model 2d 0.9 0.19 1.72 0.55 12.06
Table 3: Comparison of models based on aCRC data by treatment contrast.
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6 Illustration using simulated data
6.1 Data simulation
To demonstrate scenarios where use of bvNMA methods has an advantage over the standard sur-
rogacy models, data were simulated under different assumptions. In particular, we simulated data
where the surrogate pattern across all studies and treatments differed from the patterns within
treatment contrasts, which is detectable by mvNMA but not by BRMA. The treatment effects on
two outcomes were simulated from a bivariate normal distribution:(
Y1kli
Y2kli
)
∼ N
{(
d1kl
d2kl
)
,
(
σ21kli + τ
2
1kl σ1kliσ2kliρwkli + τ1klτ2klρ1kl,2kl
σ1kliσ2kliρwkli + τ1klτ2klρ1kl,2kl σ
2
2kli + τ
2
2kl
)}
,
as in model 1a. Two sets of network data were generated, each consisting of 30 studies, three
treatments and three treatment contrasts with 10 studies per contrast (AB, BC and AC), under
different scenarios (illustrated in Figure 4).
Scenario 1 was simulated assuming weak surrogacy when ignoring treatment contrasts but
strong surrogacy within each treatment contrast, with the following parameters: dAB = (1, 2),
dBC = (2, 1), dAC = (3, 3); σjAB(AC,BC)i ∼ Unif(0.15, 0.25), j=1,2; ρwABi = ρwBCi = ρwACi =
0.6; τ1AB = 0.3, τ1BC = τ1AC = 0.6, τ2BC = 0.3, τ2AB = τ2AC = 0.6; ρAB = ρAC = ρBC = 0.98.
Scenario 2 was simulated assuming a strong surrogacy relationship when ignoring treatment
contrasts and a mixture of either weak or strong relationships within each treatment contrast,
with the following parameters: dAB = (1, 1), dBC = (2, 2), dAC = (3, 3); σjAB(AC,BC)i ∼
Unif(0.05, 0.15), j=1,2; ρwABi = ρwBCi = ρwACi = 0.98; τ1AB = 0.2, τ1BC = 0.25, τ1AC = 0.3,
τ2AB = 0.3, τ2BC = 0.25, τ2AC = 0.2; ρAB = ρAC = 0.98 and ρBC = 0 (strong surrogacy relation-
ships for treatment contrasts AB and AC but no relationship for BC).
A
B C
Figure 4: Scatter plots of the artificial data simulated under scenario 1 (top left) and scenario 2 (top
right) and network diagram corresponding to the structure of data for both scenarios.
6.2 Results of the analysis of the simulated data
6.2.1 Scenario 1
Table 12 shows the between-studies correlations obtained by applying all models to the data simu-
lated under scenario 1. The between-studies correlation obtained from BRMA (across all studies)
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was not very high: 0.57 (95% CrI: 0.27, 0.79). Bivariate NMA with the covariance matrix varying
across treatment contrasts models the data in more detail and reveals strong correlation between
outcomes within the treatment contrasts, namely 0.79 (0.26, 0.99) for treatment contrast AB, 0.74
(0.09, 0.99) for BC and 0.85 (0.46, 0.99) for AC when using model 1a. Placing additional constraints
on the covariance matrix by assuming second order consistency in models 1b and 1c reduced un-
certainty around the correlations. Model 1d resulted in a common correlation obtained with the
highest precision, however it did not take into account the differences in the between-studies vari-
ances across the treatment contrasts, in contrast to models 1a-c as shown in Appendix F. The
right-hand-side column of Table 12 shows the across-treatment correlations ρt indicating a weak
across-treatment surrogate relationship. This is due to the differences in the surrogacy patterns
across the treatment contrasts as well as the small number of treatment contrasts. Table 5 shows
a range of statistics (described in Section 4.3.1) comparing the models in terms of their value in
predicting the treatment effect on the final outcome from the treatment effect measured on the sur-
rogate endpoint in a cross-validation procedure. The large width of the predicted interval obtained
from BRMA compared to the width of the CI of the observed treatment effect estimate is due to
high uncertainty, but the ratio wpred/wobs is reduced when using NMA models. Predicted intervals
obtained from NMA models are between 47% and 57% narrower compared to those obtained from
BRMA. The distance between the point estimate of the observed effect from the predicted effect is
also much reduced when using NMA models compared to BRMA. Figure 5 shows predicted effects
obtained (a) using BRMA and (b) from model 1a obtained with higher precision.
within-treatment surrogate relationship
model AB BC AC ρt
BRMA 0.57 (0.27, 0.79) NA
model 1a 0.79 (0.26, 0.99) 0.74 (0.09, 0.99) 0.85 (0.46, 0.99) NA
model 1b 0.88 (0.55, 0.99) 0.74 (0.22, 0.97) 0.9 (0.66, 0.99) NA
model 1c 0.87 (0.54, 0.99) 0.71 (0.17, 0.96) 0.89 (0.64, 0.99) NA
model 1d 0.92 (0.77, 0.99) NA
model 2a 0.78 (0.19, 0.99) 0.74 (0.12, 0.98) 0.85 (0.48, 0.99) 0.46 (-0.31, 0.93)
model 2b 0.88 (0.56, 0.99) 0.74 (0.23, 0.97) 0.9 (0.65, 0.99) 0.47 (-0.30, 0.93)
model 2c 0.86 (0.54, 0.99) 0.72 (0.18, 0.96) 0.89 (0.64, 0.99) 0.48 (-0.28, 0.94)
model 2d 0.92 (0.76, 0.99) 0.44 (-0.33, 0.93)
Table 4: Between-studies correlations for each model under simulation scenario 1. Where only one
value is given (models BRMA, 1d and 2d), the parameters are common across the treatment contrasts.
ρt is the correlation corresponding to the across-treatment surrogate relationship.
poverlap |mobs −mpred| wpred/wobs pi %red.
BRMA 0.98 0.69 4.03 0.25
model 1a 0.98 0.23 2.15 0.48 46.74
model 1b 0.97 0.22 1.91 0.52 52.53
model 1c 0.95 0.24 1.77 0.55 55.92
model 1d 0.94 0.24 1.69 0.56 57.88
model 2a 0.98 0.23 2.15 0.48 46.67
model 2b 0.97 0.22 1.91 0.52 52.57
model 2c 0.96 0.24 1.78 0.55 55.76
model 2d 0.94 0.24 1.69 0.56 57.97
Table 5: Comparison of models based on simulation scenario 1.
6.2.2 Scenario 2
Table 13 shows the between-studies correlations for the data simulated under scenario 2. The
overall correlation obtained from BRMA is high: 0.94 (95% CrI: 0.88, 0.98). Bivariate NMA
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a)
b)
Figure 5: Predicted effect (gray) obtained from the cross validation procedure are presented along the
observed effects: black (B vs A), red (C vs B) and blue (C vs A), obtained from (a) BRMA and (b)
model 1a for data simulated under scenario 1.
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with the variance-covariance matrix varying across treatment contrasts models the data in more
detail and reveals no correlation between the treatment effects on the two outcomes within the BC
treatment contrast. Figure 6 shows the predicted effects obtained from the cross-validation using (a)
BRMA and (b) NMA model 1a. When using the NMA model, predictions are obtained with higher
precision for contrasts AB and AC, but not BC where there was no association between the effects
on the two outcomes and which is reflected by the wide predicted intervals. The across-treatment
correlations ρt in the right-hand-side column of Table 13 are obtained with high uncertainty due to
the small number of treatment contrasts to estimate the correlation. Table 7 shows the statistics
for the model comparison in terms of their predictive value, obtained from the cross-validation
procedure. Similarly as in scenario 1, the large ratio, wpred/wobs, comparing the width of the
predicted interval obtained from BRMA with the width of the CI of the observed treatment effect
estimate is reduced when using the NMA models. Predicted intervals obtained from NMA models
are between 19.6% and 29.3% narrower compared to those obtained from BRMA. The distance
between the point estimate of the observed effect and the predicted effect is slightly reduced when
using NMA models 1a-c and 2a-c compared to BRMA. These improvements, on average, are not as
strong as in scenario 1, due to poor association for the treatment contrast BC. When investigating
these statistics within the treatment contrasts, the improvement is largest for contrast AC where
the correlation was highest (these results are presented in Appendix G).
within-treatment surrogate relationship
model AB BC AC ρt
BRMA 0.94 (0.88, 0.98) NA
model 1a 0.81 (0.34, 0.99) -0.19 (-0.73, 0.43) 0.87 (0.49, 0.99) NA
model 1b 0.78 (0.2, 0.99) -0.05 (-0.6, 0.53) 0.8 (0.26, 0.99) NA
model 1c 0.77 (0.22, 0.98) -0.11 (-0.62, 0.43) 0.79 (0.3, 0.99) NA
model 1d 0.39 (0, 0.69) NA
model 2a 0.81 (0.32, 0.99) -0.2 (-0.75, 0.44) 0.87 (0.47, 0.99) 0.56 (-0.25, 0.99)
model 2b 0.77 (0.19, 0.99) -0.04 (-0.59, 0.54) 0.79 (0.26, 0.99) 0.58 (-0.22, 0.99)
model 2c 0.78 (0.25, 0.99) -0.11 (-0.62, 0.42) 0.79 (0.29, 0.98) 0.59 (-0.26, 0.99)
model 2d 0.39 (0, 0.69) 0.57 (-0.27, 0.99)
Table 6: Between-studies correlations for each model under simulation scenario 2. Where only one
value is given (models BRMA, 1d and 2d), the parameters are common across the treatment contrasts.
ρt is the correlation corresponding to the across-treatment surrogate relationship.
poverlap |mobs −mpred| wpred/wobs pi %red.
BRMA 0.9 0.2 3.55 0.27
model 1a 0.97 0.16 2.84 0.41 20.2
model 1b 0.95 0.17 2.76 0.38 21.86
model 1c 0.93 0.17 2.5 0.41 29.16
model 1d 0.9 0.2 2.87 0.33 19.5
model 2a 0.98 0.16 2.83 0.41 20.32
model 2b 0.95 0.17 2.77 0.38 21.86
model 2c 0.93 0.17 2.49 0.41 29.34
model 2d 0.9 0.2 2.87 0.33 19.61
Table 7: Comparison of models based on simulation scenario 2.
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a)
b)
Figure 6: Predicted effect (gray) obtained from the cross validation procedure are presented along the
observed effects: black (B vs A), red (C vs B) and blue (C vs A), obtained from (a) BRMA and (b)
model 1a for data simulated under scenario 2.
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7 Discussion
We have developed bivariate network meta-analytic models for surrogate endpoint evaluation to
allow for a more detailed modelling of surrogate relationships within and across treatment con-
trasts. This methodology can help to disentangle information about surrogate relationships in data
scenarios where such relationships vary across treatment contrasts and are distinct in comparison
with an association pattern across treatments. Two types of surrogacy have been described by the
models: surrogacy across patient populations for a given treatment contrast and surrogacy across
treatments. The models will allow analysts to make predictions of the treatment effect on the final
clinical outcome from the observed effect on a surrogate endpoint in a new study investigating the
effectiveness of an existing treatment in a new setting or a new treatment.
There are some limitations to the models presented here. For simplicity, we focused on the
models for data from two-arm studies. The methods can be extended to model multi-arm trial
data in a similar manner as in Achana et al. [1]. Another limitation is related to the prior
distribution for the ancillary variance-covariance matrix in model 1b, introduced to allow for the
second order consistency constraints. It was based on the Cholesky decomposition which results
in the prior distributions for the between-studies correlations being dependent on the ordering of
the treatments in the network. We carried out a sensitivity analysis by changing the ordering of
treatments in the illustrative example in aCRC; the results remained very similar to those obtained
from the main analysis. Scarcity of data may also present a problem in fitting the models. For
estimation of the surrogate relationships within the treatment contrasts, a relatively large number
of trials per treatment contrast is needed, whereas for the across-treatment surrogacy, a range of
treatments needs to be included in the network.
Nevertheless, we believe that the models have great potential for making improvements in the
research area of surrogate endpoint evaluation. In our example in aCRC, the models allowed us to
disentangle information on a relatively strong surrogate relationship between treatment effects on
TR and PFS for the treatment contrast of EGFRi with chemotherapy vs. chemotherapy alone from
a set of treatments with suboptimal overall surrogacy relationship. Moreover, in medical decision-
making, where multiple comparisons of new health technologies against different comparators play
an important role, NMA is a valuable tool in obtaining average effects across all treatment contrasts
in the network of treatments. In a similar way, our proposed methodology can be used to predict
the effect of a new treatment on the final clinical outcome against any comparator in the network.
In conclusion, we developed a new meta-analytic method for surrogate endpoint evaluation that
allows modelling of surrogate relationships in greater detail.
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A Beta distribution based prior for the correlation
A beta distribution was used to construct prior distributions for the between-studies correlations
(all models) and for the correlation between effects on treatment arms (models 2a–c). A random
variable drawn from a beta distribution r ∼ Beta(1.5, 1.5) is limited to values between 0 and 1 with
probability density zero on the edges and mean value of 0.5, as seen in Figure 7 (left). Transforming
this variable, such as ρ = r ∗ 2 − 1, gives a distribution bounded by −1 and 1 with mean at zero,
as shown in Figure 7 (right). This can be used as a prior distribution for the between-studies
correlation, as in Burke et al (2016). The resulting prior distribution for the correlation, such as
Figure 7: Beta distribution
ρ+1
2 ∼ Beta(1.5, 1.5), allows for positive and negative values of the between-study correlation and
it is relatively flat across the range of values, with the exception that values at the extreme ends
of the distribution are considered extremely unlikely.
B Surrogacy criteria
Daniels and Hughes defined the surrogacy criteria for a Bayesian meta-analytic model where the
relationship between the true treatment effects on final clinical outcome µ2i and the effect on the
surrogate endpoint µ1i was written in the form of a linear regression:
µ2i|µ1i ∼ N(λ0 + λ1µ1i, ψ2). (21)
The surrogate relationship between the two treatment effects, µ2i and µ1i, was perfect if the in-
tercept λ0 was zero, as then a zero effect on a surrogate would imply a zero effect on the final
outcome, the slope λ1 should not be zero for the association to be strong, with the conditional
variance ψ2 being zero. For the complete model see Daniels and Hughes (1997). A similar re-
lationship and surrogacy criteria were described by Bujkiewicz et al (2015) in the framework of
bivariate meta-analysis and extended by Bujkiewicz et al (2016) to multivariate meta-analysis. In
the two papers the relationship between the regression parameters and the elements of the between-
studies variance-covariance matrix was defined, similarly as in Bujkiewicz et al (2013). The derived
relationships in the bivariate case are
λ1 = ρ1
τ2
τ1
(22)
and
ψ2 = τ22 − λ21τ21 . (23)
If the surrogacy relationship is perfect, the conditional variance is zero: ψ2 = 0 (Daniels and
Hughes (1997), Bujkiewicz et al (2015)). Hence, from (23), τ22 = λ
2
1τ
2
1 which gives λ1 = ± τ2τ1 , and
from (22) it implies that the correlation ρ = ±1. Also ρ2 = 1, which some authors refer to as the
study level adjusted R-squared (Burzykowski et al (2001), Renfro et al (2012)).
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A B
n
Figure 8: Example network diagram: all n studies include the same treatment contrast (only two
treatments) (left).
C Relationships between the models
The models reduce to the standard meta-analysis model for surrogate endpoints, such as the BRMA
model, in a special case of data structure. When there are only two treatments in the network, as
depicted in Figure 8, it can be shown that model 1a reduces to BRMA. Equations (3)–(4) become(
Y1(12)i
Y2(12)i
)
∼ N
((
µ1(12)i
µ2(12)i
)
,
(
σ21(12)i σ1(12)iσ2(12)iρwi(12)
σ1(12)iσ2(12)iρwi(12) σ
2
2(12)i
))
(24)
(
µ1(12)i
µ2(12)i
)
∼ MVN
((
d1(12)
d2(12)
)
,
(
τ21(12) τ1(12)τ2(12)ρ(12)
τ1(12)τ2(12)ρ(12) τ
2
2(12)
))
(25)
The index (12) denoting the two treatments does not vary across studies or contrasts and hence
can be dropped, resulting in equations for BRMA – equations (3.1)–(3.2) in the main manuscript,
with dj = βj and j = 1, 2.
D Additional results: aCRC example
Tables 8 and 9 give additional resuts to the illustrative example in aCRC. Figure 3 shows the
predicted effects obtained from BRMA and model 2d along with the observed estimates of the
effects on PFS. The improvement in predictions was not substantial due to the weak association
patterns between the treatment effects on the two outcomes.
22
model AB AC BC BD
log OR (TR)
BRMA 0.54 (0.36, 0.72)
model 1a 0.49 (0.26, 0.73) 0.81 (0.57, 1.08) 0.33 (0.09, 0.57) 0.16 (-0.67, 0.95)
model 1b 0.47 (0.22, 0.74) 0.79 (0.53, 1.07) 0.31 (0.03, 0.6) 0.15 (-0.73, 0.95)
model 1c 0.46 (0.24, 0.69) 0.77 (0.55, 1) 0.31 (0.06, 0.55) 0.19 (-0.28, 0.63)
model 1d 0.49 (0.21, 0.77) 0.74 (0.48, 1) 0.25 (-0.09, 0.58) 0.18 (-0.39, 0.75)
model 2a 0.45 (0.22, 0.69) 0.76 (0.49, 1.02) 0.3 (0.06, 0.53) 0.11 (-0.45, 0.65)
model 2b 0.44 (0.18, 0.69) 0.72 (0.45, 0.99) 0.28 (0.01, 0.55) 0.1 (-0.46, 0.63)
model 2c 0.43 (0.21, 0.65) 0.72 (0.49, 0.94) 0.29 (0.06, 0.51) 0.15 (-0.23, 0.52)
model 2d 0.45 (0.18, 0.72) 0.68 (0.44, 0.93) 0.23 (-0.07, 0.54) 0.12 (-0.34, 0.6)
log HR (PFS)
BRMA -0.24 (-0.33, -0.16)
model 1a -0.37 (-0.47, -0.27) -0.31 (-0.42, -0.2) 0.06 (-0.05, 0.18) 0.09 (-0.33, 0.51)
model 1b -0.37 (-0.48, -0.26) -0.3 (-0.41, -0.18) 0.07 (-0.05, 0.21) 0.09 (-0.28, 0.49)
model 1c -0.37 (-0.46, -0.27) -0.3 (-0.4, -0.2) 0.07 (-0.04, 0.19) 0.08 (-0.14, 0.3)
model 1d -0.38 (-0.51, -0.26) -0.28 (-0.39, -0.18) 0.1 (-0.05, 0.25) 0.11 (-0.15, 0.37)
model 2a -0.35 (-0.45, -0.24) -0.29 (-0.4, -0.18) 0.06 (-0.05, 0.17) 0.1 (-0.16, 0.37)
model 2b -0.34 (-0.45, -0.23) -0.28 (-0.39, -0.17) 0.07 (-0.05, 0.2) 0.1 (-0.14, 0.36)
model 2c -0.34 (-0.44, -0.24) -0.28 (-0.38, -0.18) 0.06 (-0.04, 0.17) 0.09 (-0.09, 0.28)
model 2d -0.35 (-0.47, -0.23) -0.27 (-0.37, -0.17) 0.08 (-0.05, 0.22) 0.13 (-0.09, 0.34)
Var(log OR) (TR)
BRMA 0.3 (0.16, 0.52)
model 1a 0.23 (0.08, 0.59) 0.58 (0.23, 1.26) 0.11 (0, 0.8) 0.87 (0.03, 3.32)
model 1b 0.31 (0.11, 0.7) 0.45 (0.2, 0.88) 0.13 (0, 0.58) 0.71 (0.04, 3.01)
model 1c 0.24 (0.09, 0.49) 0.32 (0.15, 0.62) 0.07 (0, 0.32) 0.15 (0.01, 0.52)
model 1d 0.3 (0.15, 0.55)
model 2a 0.23 (0.07, 0.56) 0.59 (0.23, 1.31) 0.12 (0, 0.85) 0.76 (0.02, 3.16)
model 2b 0.31 (0.11, 0.68) 0.44 (0.2, 0.86) 0.13 (0, 0.56) 0.6 (0.03, 2.66)
model 2c 0.23 (0.09, 0.45) 0.3 (0.15, 0.56) 0.06 (0, 0.23) 0.13 (0.01, 0.5)
model 2d 0.29 (0.15, 0.53)
Var(log HR) (PFS)
BRMA 0.08 (0.04, 0.13)
model 1a 0.03 (0.01, 0.09) 0.11 (0.05, 0.21) 0.04 (0, 0.3) 0.24 (0, 1.47)
model 1b 0.05 (0.01, 0.12) 0.09 (0.04, 0.16) 0.03 (0, 0.12) 0.16 (0.01, 0.92)
model 1c 0.04 (0.01, 0.08) 0.06 (0.03, 0.11) 0.02 (0, 0.07) 0.03 (0, 0.13)
model 1d 0.06 (0.03, 0.1)
model 2a 0.03 (0.01, 0.1) 0.11 (0.05, 0.22) 0.03 (0, 0.2) 0.18 (0.01, 1.03)
model 2b 0.05 (0.01, 0.12) 0.08 (0.04, 0.16) 0.03 (0, 0.12) 0.12 (0.01, 0.61)
model 2c 0.04 (0.01, 0.08) 0.06 (0.03, 0.11) 0.02 (0, 0.06) 0.03 (0, 0.11)
model 2d 0.06 (0.03, 0.1)
Table 8: Mean effects and the between-studies variances for each model in the aCRC example. A –
chemotherapy alone, B – anti-VEGF therapies + chemotherapy, C – EGFRi + chemotherapy, D –
EGFRi + anti-VEGF therapies + chemotherapy.
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model AE AD CF
log OR (TR)
model 1a 1.4 (-1.86, 4.66) 0.64 (-0.2, 1.46) -0.01 (-1.49, 1.49)
model 1b 1.41 (-2.02, 4.82) 0.62 (-0.28, 1.45) -0.01 (-1.56, 1.54)
model 1c 1.39 (-1.08, 3.87) 0.65 (0.14, 1.14) -0.02 (-0.7, 0.66)
model 1d 1.42 (-1.06, 3.88) 0.67 (0.05, 1.28) -0.02 (-0.92, 0.88)
model 2a 0.57 (-0.38, 1.75) 0.56 (-0.01, 1.14) -0.16 (-0.85, 0.5)
model 2b 0.54 (-0.45, 1.74) 0.54 (-0.04, 1.1) -0.16 (-0.87, 0.53)
model 2c 0.57 (-0.3, 1.7) 0.58 (0.16, 0.99) -0.12 (-0.6, 0.39)
model 2d 0.57 (-0.32, 1.75) 0.57 (0.08, 1.08) -0.12 (-0.72, 0.52)
log HR (PFS)
model 1a 0 (-2.55, 2.55) -0.28 (-0.7, 0.15) 0.12 (-1.21, 1.46)
model 1b 0.01 (-2.58, 2.61) -0.27 (-0.66, 0.13) 0.11 (-1.24, 1.47)
model 1c 0 (-0.7, 0.68) -0.28 (-0.52, -0.05) 0.11 (-0.24, 0.47)
model 1d 0 (-0.69, 0.69) -0.27 (-0.55, 0.01) 0.11 (-0.31, 0.54)
model 2a -0.19 (-0.71, 0.32) -0.24 (-0.52, 0.03) 0.08 (-0.3, 0.45)
model 2b -0.19 (-0.69, 0.33) -0.24 (-0.5, 0.02) 0.07 (-0.31, 0.45)
model 2c -0.14 (-0.51, 0.28) -0.25 (-0.45, -0.05) 0.09 (-0.17, 0.35)
model 2d -0.13 (-0.5, 0.31) -0.23 (-0.46, -0.01) 0.1 (-0.19, 0.4)
correlations
model 1a 0 (-0.88, 0.88) 0 (-0.89, 0.89) 0.01 (-0.9, 0.9)
model 1b -0.08 (-0.89, 0.83) -0.32 (-0.95, 0.72) -0.02 (-0.84, 0.82)
model 1c -0.48 (-0.96, 0.64) -0.46 (-0.96, 0.64) -0.15 (-0.87, 0.75)
model 2a 0.02 (-0.87, 0.89) -0.01 (-0.89, 0.88) 0 (-0.9, 0.9)
model 2b -0.07 (-0.89, 0.84) -0.35 (-0.95, 0.7) -0.04 (-0.85, 0.82)
model 2c -0.5 (-0.96, 0.57) -0.49 (-0.96, 0.56) -0.14 (-0.86, 0.75)
Var(log OR) (TR)
model 1a 1.33 (0, 3.81) 0.98 (0, 3.65) 0.79 (0, 3.49)
model 1b 1.67 (0.09, 5.19) 0.89 (0.04, 3.51) 0.92 (0.01, 3.74)
model 1c 0.31 (0.02, 1.07) 0.29 (0.02, 0.92) 0.14 (0, 0.62)
model 2a 1.21 (0, 3.75) 0.95 (0, 3.64) 0.63 (0, 3.31)
model 2b 1.5 (0.08, 4.92) 0.78 (0.03, 3.13) 0.7 (0.01, 3.42)
model 2c 0.28 (0.03, 0.96) 0.27 (0.03, 0.84) 0.1 (0, 0.46)
Var(log HR) (PFS)
model 1a 1.34 (0, 3.81) 0.81 (0, 3.56) 0.67 (0, 3.49)
model 1b 1.38 (0.02, 4.01) 0.19 (0.01, 0.97) 0.72 (0, 3.51)
model 1c 0.06 (0, 0.22) 0.05 (0, 0.18) 0.03 (0, 0.14)
model 2a 0.85 (0, 3.57) 0.79 (0, 3.56) 0.36 (0, 2.7)
model 2b 0.91 (0.01, 3.69) 0.15 (0.01, 0.67) 0.39 (0, 2.75)
model 2c 0.05 (0, 0.19) 0.05 (0, 0.17) 0.03 (0, 0.12)
Table 9: Mean effects and the between-studies correlations and variances for each model in the aCRC
example (contrasts AE, AD and CF). A – chemotherapy alone, C – EGFRi + chemotherapy, D –
EGFRi + anti-VEGF therapies + chemotherapy, E – anti-IGF1R , F – anti-IgG2 + chemotherapy
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E Sensitivity analysis (aCRC example)
Sensitivity analysis was carried out investigating the effect of potentially influential observations
(three studies with largest treatment effect on TR, due to no events in the control arm, were
removed). Figure E shows the scatter plot. Tables 10 and 11 show the between studies correlations
of the heterogeneity parameters.
B A
D C F
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15
21
4
4
1
1
2
Figure 9: Scatter plot and network diagram for the advanced colorectal cancer example, A – chemother-
apy alone, B – anti-VEGF therapies + chemotherapy, C – EGFRi + chemotherapy, D – EGFRi +
anti-VEGF therapies + chemotherapy, E – anti-IGF1R , F – anti-IgG2 + chemotherapy
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model AB BC AC BD
log OR (TR)
BRMA 0.48 (0.32, 0.65)
model 1a 0.43 (0.2, 0.67) 0.71 (0.46, 0.96) 0.28 (0, 0.52) 0.16 (-0.69, 0.95)
model 1b 0.42 (0.17, 0.67) 0.68 (0.43, 0.93) 0.26 (-0.04, 0.52) 0.16 (-0.7, 0.95)
model 1c 0.41 (0.19, 0.64) 0.68 (0.45, 0.9) 0.27 (0, 0.5) 0.19 (-0.3, 0.64)
model 1d 0.46 (0.2, 0.72) 0.63 (0.39, 0.86) 0.17 (-0.15, 0.48) 0.18 (-0.36, 0.72)
model 2a 0.39 (0.15, 0.63) 0.65 (0.39, 0.9) 0.26 (-0.01, 0.48) 0.11 (-0.43, 0.66)
model 2b 0.38 (0.13, 0.64) 0.62 (0.36, 0.87) 0.24 (-0.05, 0.49) 0.1 (-0.44, 0.62)
model 2c 0.37 (0.15, 0.6) 0.63 (0.4, 0.85) 0.25 (0.02, 0.47) 0.15 (-0.24, 0.51)
model 2d 0.42 (0.17, 0.67) 0.58 (0.34, 0.81) 0.16 (-0.13, 0.45) 0.1 (-0.33, 0.56)
log HR (PFS)
BRMA -0.21 (-0.29, -0.12)
model 1a -0.35 (-0.45, -0.24) -0.24 (-0.36, -0.13) 0.11 (-0.01, 0.26) 0.09 (-0.35, 0.52)
model 1b -0.35 (-0.45, -0.24) -0.23 (-0.34, -0.13) 0.11 (-0.01, 0.25) 0.08 (-0.3, 0.47)
model 1c -0.34 (-0.44, -0.25) -0.23 (-0.33, -0.14) 0.11 (0.01, 0.23) 0.08 (-0.13, 0.3)
model 1d -0.36 (-0.47, -0.25) -0.21 (-0.31, -0.12) 0.15 (0.02, 0.28) 0.1 (-0.12, 0.33)
model 2a -0.32 (-0.43, -0.21) -0.23 (-0.34, -0.12) 0.09 (-0.02, 0.23) 0.11 (-0.15, 0.37)
model 2b -0.32 (-0.43, -0.2) -0.22 (-0.32, -0.12) 0.1 (-0.01, 0.23) 0.1 (-0.14, 0.35)
model 2c -0.32 (-0.41, -0.21) -0.22 (-0.31, -0.13) 0.09 (-0.01, 0.2) 0.09 (-0.08, 0.26)
model 2d -0.33 (-0.44, -0.23) -0.2 (-0.3, -0.11) 0.13 (0.01, 0.25) 0.12 (-0.07, 0.31)
correlations
BRMA -0.67 (-0.87, -0.4)
model 1a -0.53 (-0.91, 0.05) -0.74 (-0.96, -0.34) -0.03 (-0.89, 0.87) -0.28 (-0.94, 0.65)
model 1b -0.66 (-0.95, -0.13) -0.76 (-0.96, -0.41) -0.21 (-0.89, 0.71) -0.28 (-0.9, 0.58)
model 1c -0.66 (-0.95, -0.16) -0.76 (-0.97, -0.4) -0.19 (-0.87, 0.7) -0.32 (-0.89, 0.51)
model 1d -0.76 (-0.94, -0.47)
model 2a -0.55 (-0.92, 0.03) -0.73 (-0.95, -0.32) -0.03 (-0.9, 0.88) -0.3 (-0.95, 0.65)
model 2b -0.67 (-0.95, -0.15) -0.77 (-0.96, -0.41) -0.2 (-0.89, 0.72) -0.3 (-0.89, 0.55)
model 2c -0.71 (-0.96, -0.27) -0.81 (-0.97, -0.52) -0.25 (-0.89, 0.68) -0.3 (-0.89, 0.54)
model 2d -0.76 (-0.95, -0.49)
Var(log OR) (TR)
BRMA 0.26 (0.14, 0.43)
model 1a 0.23 (0.07, 0.59) 0.41 (0.17, 0.89) 0.13 (0, 0.91) 0.86 (0.03, 3.33)
model 1b 0.27 (0.1, 0.58) 0.34 (0.16, 0.66) 0.12 (0, 0.56) 0.69 (0.04, 2.99)
model 1c 0.21 (0.08, 0.44) 0.26 (0.12, 0.49) 0.07 (0, 0.32) 0.16 (0.01, 0.57)
model 1d 0.24 (0.13, 0.43)
model 2a 0.25 (0.08, 0.61) 0.4 (0.17, 0.83) 0.13 (0, 0.9) 0.75 (0.02, 3.1)
model 2b 0.27 (0.1, 0.58) 0.34 (0.16, 0.66) 0.12 (0, 0.52) 0.59 (0.03, 2.58)
model 2c 0.23 (0.09, 0.45) 0.3 (0.15, 0.56) 0.06 (0, 0.23) 0.13 (0.01, 0.5)
model 2d 0.24 (0.13, 0.4)
Var(log HR) (PFS)
BRMA 0.06 (0.03, 0.1)
model 1a 0.03 (0.01, 0.1) 0.06 (0.02, 0.15) 0.06 (0, 0.42) 0.26 (0.01, 1.71)
model 1b 0.04 (0.01, 0.1) 0.05 (0.02, 0.11) 0.03 (0, 0.1) 0.16 (0.01, 0.88)
model 1c 0.03 (0.01, 0.07) 0.04 (0.01, 0.08) 0.02 (0, 0.06) 0.03 (0, 0.09)
model 1d 0.04 (0.02, 0.07)
model 2a 0.04 (0.01, 0.11) 0.06 (0.02, 0.14) 0.05 (0, 0.32) 0.18 (0.01, 1.02)
model 2b 0.04 (0.01, 0.1) 0.05 (0.02, 0.11) 0.02 (0, 0.09) 0.12 (0.01, 0.62)
model 2c 0.04 (0.01, 0.08) 0.06 (0.03, 0.11) 0.02 (0, 0.06) 0.03 (0, 0.11)
model 2d 0.04 (0.02, 0.07)
Table 10: Between-studies correlations for each model in the aCRC example. Where only one value
is given (models BRMA, 1d and 2d), the parameters are common across the treatment contrasts.
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model AE AD CF
log OR (TR)
model 1a 1.41 (-1.82, 4.64) 0.59 (-0.27, 1.39) -0.02 (-1.55, 1.52)
model 1b 1.42 (-1.95, 4.79) 0.58 (-0.3, 1.4) -0.02 (-1.55, 1.5)
model 1c 1.4 (-1.04, 3.86) 0.61 (0.09, 1.1) -0.02 (-0.67, 0.63)
model 1d 1.44 (-1.01, 3.88) 0.64 (0.06, 1.21) -0.02 (-0.85, 0.8)
model 2a 0.52 (-0.41, 1.72) 0.51 (-0.06, 1.08) -0.13 (-0.8, 0.52)
model 2b 0.5 (-0.41, 1.68) 0.49 (-0.07, 1.05) -0.14 (-0.81, 0.53)
model 2c 0.51 (-0.29, 1.55) 0.52 (0.1, 0.93) -0.11 (-0.57, 0.37)
model 2d 0.5 (-0.33, 1.62) 0.52 (0.07, 1.02) -0.1 (-0.66, 0.5)
log HR (PFS)
model 1a 0.01 (-2.55, 2.53) -0.26 (-0.7, 0.18) 0.11 (-1.18, 1.38)
model 1b 0 (-2.57, 2.58) -0.26 (-0.65, 0.13) 0.11 (-1.25, 1.48)
model 1c -0.01 (-0.66, 0.64) -0.26 (-0.49, -0.03) 0.12 (-0.22, 0.46)
model 1d 0 (-0.64, 0.63) -0.26 (-0.5, -0.02) 0.11 (-0.25, 0.48)
model 2a -0.16 (-0.65, 0.33) -0.22 (-0.5, 0.05) 0.06 (-0.29, 0.41)
model 2b -0.17 (-0.66, 0.32) -0.22 (-0.47, 0.04) 0.06 (-0.31, 0.41)
model 2c -0.13 (-0.46, 0.24) -0.23 (-0.41, -0.04) 0.07 (-0.15, 0.31)
model 2d -0.11 (-0.46, 0.29) -0.22 (-0.42, -0.02) 0.08 (-0.18, 0.35)
correlations
model 1a 0 (-0.88, 0.88) -0.01 (-0.89, 0.89) 0.02 (-0.88, 0.9)
model 1b -0.06 (-0.87, 0.83) -0.27 (-0.94, 0.75) -0.02 (-0.83, 0.82)
model 1c -0.42 (-0.96, 0.69) -0.38 (-0.95, 0.69) -0.11 (-0.85, 0.77)
model 2a 0.02 (-0.88, 0.89) -0.02 (-0.89, 0.88) -0.01 (-0.91, 0.89)
model 2b -0.06 (-0.88, 0.84) -0.32 (-0.94, 0.72) -0.02 (-0.83, 0.81)
model 2c -0.5 (-0.96, 0.57) -0.49 (-0.96, 0.56) -0.14 (-0.86, 0.75)
Var(log OR) (TR)
model 1a 1.34 (0, 3.8) 0.99 (0, 3.67) 0.85 (0, 3.6)
model 1b 1.6 (0.07, 4.93) 0.81 (0.03, 3.32) 0.91 (0.01, 3.72)
model 1c 0.26 (0.02, 0.96) 0.25 (0.02, 0.9) 0.11 (0, 0.51)
model 2a 1.19 (0, 3.74) 0.94 (0, 3.64) 0.58 (0, 3.19)
model 2b 1.45 (0.06, 4.73) 0.72 (0.03, 2.94) 0.66 (0.01, 3.33)
model 2c 0.28 (0.03, 0.96) 0.27 (0.03, 0.84) 0.1 (0, 0.46)
Var(log HR) (PFS)
model 1a 1.33 (0, 3.8) 0.81 (0, 3.57) 0.63 (0, 3.39)
model 1b 1.37 (0.02, 3.93) 0.17 (0, 0.91) 0.7 (0, 3.48)
model 1c 0.04 (0, 0.17) 0.04 (0, 0.13) 0.03 (0, 0.11)
model 2a 0.83 (0, 3.57) 0.8 (0, 3.54) 0.33 (0, 2.55)
model 2b 0.87 (0.01, 3.63) 0.14 (0.01, 0.66) 0.36 (0, 2.63)
model 2c 0.05 (0, 0.19) 0.05 (0, 0.17) 0.03 (0, 0.12)
Table 11: Between-studies correlations and variances for each model in the aCRC example (contrasts
AE, AD and CF).
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F Additional results: simulated scenario 1
model AB BC AC
surrogate endpoint Y1
BRMA 0.91 (0.52, 1.56)
model 1a 0.13 (0.02, 0.4) 0.25 (0.07, 0.67) 0.47 (0.17, 1.15)
model 1b 0.15 (0.03, 0.44) 0.23 (0.08, 0.52) 0.46 (0.19, 0.94)
model 1c 0.10 (0.03, 0.25) 0.16 (0.06, 0.34) 0.32 (0.15, 0.61)
model 1d 0.25 (0.13, 0.45)
model 2a 0.13 (0.02, 0.39) 0.26 (0.08, 0.70) 0.48 (0.16, 1.23)
model 2b 0.16 (0.03, 0.45) 0.23 (0.08, 0.53) 0.46 (0.18, 0.94)
model 2c 0.09 (0.02, 0.24) 0.16 (0.06, 0.35) 0.33 (0.15, 0.61)
model 2d 0.25 (0.13, 0.44)
final outcome Y2
BRMA 0.93 (0.53, 1.6)
model 1a 0.4 (0.12, 1.11) 0.09 (0.01, 0.3) 0.4 (0.14, 1.00)
model 1b 0.33 (0.13, 0.72) 0.10 (0.02, 0.31) 0.45 (0.17, 0.93)
model 1c 0.22 (0.10, 0.45) 0.07 (0.01, 0.19) 0.31 (0.14, 0.59)
model 1d 0.26 (0.13, 0.47)
model 2a 0.41 (0.13, 1.10) 0.09 (0.01, 0.30) 0.41 (0.13, 1.10)
model 2b 0.33 (0.13, 0.71) 0.1 (0.02, 0.32) 0.45 (0.17, 0.94)
model 2c 0.22 (0.10, 0.45) 0.06 (0.01, 0.18) 0.31 (0.13, 0.59)
model 2d 0.25 (0.13, 0.47)
Table 12: Heterogeneity parameters for each model under simulation scenario 1. Where only one value
is given (models BRMA, 1d and 2d), the parameters are common across the treatment contrasts.
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G Additional results: simulated scenario 2
model AB BC AC
surrogate endpoint Y1
BRMA 0.85 (0.50, 1.42)
model 1a 0.04 (0.01, 0.11) 0.12 (0.04, 0.34) 0.11 (0.04, 0.26)
model 1b 0.05 (0.01, 0.14) 0.08 (0.03, 0.17) 0.14 (0.05, 0.28)
model 1c 0.03 (0.01, 0.09) 0.06 (0.03, 0.12) 0.1 (0.05, 0.20)
model 1d 0.08 (0.04, 0.14)
model 2a 0.04 (0.01, 0.11) 0.12 (0.04, 0.34) 0.11 (0.04, 0.28)
model 2b 0.05 (0.01, 0.13) 0.08 (0.03, 0.18) 0.14 (0.05, 0.28)
model 2c 0.03 (0.01, 0.08) 0.06 (0.03, 0.12) 0.10 (0.05, 0.20)
model 2d 0.08 (0.04, 0.14)
final outcome Y2
BRMA 0.81 (0.48, 1.36)
model 1a 0.08 (0.02, 0.21) 0.12 (0.04, 0.33) 0.04 (0.01, 0.12)
model 1b 0.12 (0.04, 0.27) 0.07 (0.03, 0.16) 0.05 (0.02, 0.12)
model 1c 0.09 (0.03, 0.19) 0.05 (0.02, 0.11) 0.04 (0.01, 0.08)
model 1d 0.07 (0.03, 0.12)
model 2a 0.08 (0.02, 0.21) 0.12 (0.04, 0.35) 0.05 (0.01, 0.12)
model 2b 0.12 (0.04, 0.26) 0.07 (0.03, 0.16) 0.05 (0.02, 0.12)
model 2c 0.09 (0.03, 0.18) 0.05 (0.02, 0.11) 0.04 (0.01, 0.09)
model 2d 0.07 (0.03, 0.12)
Table 13: Heterogeneity parameters for each model under simulation scenario 2. Where only one value
is given (models BRMA, 1d and 2d), the parameters are common across the treatment contrasts.
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poverlap |mobs −mpred| wpred/wobs pi %red.
AB
BRMA 1 0.13 3.35 0.31
model 1a 0.99 0.13 2.37 0.43 28.61
model 1b 1 0.11 2.81 0.37 15.44
model 1c 1 0.12 2.59 0.4 21.99
model 1d 0.98 0.19 2.63 0.39 21.53
model 2a 0.99 0.13 2.35 0.43 29.02
model 2b 1 0.11 2.82 0.37 15.23
model 2c 1 0.12 2.59 0.4 21.97
model 2d 0.98 0.19 2.63 0.39 21.63
BC
BRMA 0.69 0.37 3.53 0.21
model 1a 0.95 0.29 4.23 0.24 -17.64
model 1b 0.86 0.3 3.31 0.28 7.33
model 1c 0.83 0.3 2.94 0.3 17.79
model 1d 0.71 0.31 2.93 0.26 17.28
model 2a 0.95 0.29 4.22 0.24 -17.53
model 2b 0.86 0.3 3.31 0.28 7.46
model 2c 0.83 0.3 2.93 0.3 17.98
model 2d 0.71 0.31 2.92 0.26 17.47
AC
BRMA 1 0.09 3.77 0.28
model 1a 0.99 0.08 1.91 0.55 49.62
model 1b 1 0.09 2.17 0.49 42.81
model 1c 0.98 0.09 1.97 0.52 47.71
model 1d 1 0.11 3.05 0.35 19.67
model 2a 0.99 0.08 1.92 0.55 49.47
model 2b 1 0.09 2.17 0.49 42.88
model 2c 0.97 0.09 1.96 0.53 48.07
model 2d 1 0.1 3.04 0.35 19.74
Table 14: Comparison of models based on simulation scenario 2 by treatment contrast.
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